PDF(Pubmed)
Abstract：
Bladder cancer (BC) is the 12th most commonly diagnosed cancer worldwide. Although there are several well-established molecular and immunological classifications, prognostic and predictive markers for tumor cells and immune cells are still needed. Using a tissue microarray, we analyzed the expression of the chemokine CC motif ligand 5 (CCL5) by immunohistochemistry (IHC) in 175 muscle-invasive BC samples. The application of a single cutoff for the staining status of tumor cells (TCs; positive vs. negative) and immune cells (ICs; positive vs. negative) revealed 75 patients (42.9%) and 123 patients (70.3%) with CCL5-positive TCs or ICs, respectively. IHC results were associated with prognostic and predictive data. Multivariate Cox regression analysis revealed that positive CCL5 staining in TCs was associated with significantly shorter disease-specific survival (DSS; RR = 1.51; p = 0.047), but CCL5-negative ICs were associated with significantly shorter overall survival (OS; RR = 1.66; p = 0.005), DSS (RR = 2.02; p = 0.001) and recurrence-free survival (RFS; RR = 1.94; p = 0.002). Adjuvant chemotherapy was favorable for patients with CCL5-negative ICs for OS (RR = 0.30; p = 0.006), DSS (RR = 0.36; p = 0.022) and RFS (RR = 0.41; p = 0.046) but not for patients with CCL5-positive ICs, except in the subgroup of N1 + N2 patients, where it was associated with better OS. We suggest that CCL5 expression can be a prognostic and predictive marker for muscle-invasive bladder cancer patients.
摘要：
膀胱癌（BC）是世界上第12位最常诊断的癌症。虽然有几个完善的分子和免疫学分类，肿瘤细胞和免疫细胞的预后和预测标志物仍然需要.使用组织微阵列，我们通过免疫组织化学(IHC)分析了175例肌肉侵袭性BC样本中趋化因子CC基序配体5(CCL5)的表达.肿瘤细胞染色状态的单一截止值的应用(TCs；阳性与阴性)和免疫细胞(IC；阳性与阴性）显示有CCL5阳性TC或IC的75例患者（42.9％）和123例患者（70.3％），分别。IHC结果与预后和预测数据相关。多因素Cox回归分析显示，TC中CCL5染色阳性与疾病特异性生存期显著缩短相关(DSS;RR=1.51;p=0.047)。但CCL5阴性IC与总生存期显著缩短相关(OS;RR=1.66;p=0.005),DSS(RR=2.02;p=0.001)和无复发生存期(RFS;RR=1.94;p=0.002)。辅助化疗对CCL5阴性IC的OS患者有利（RR=0.30；p=0.006），DSS（RR=0.36;p=0.022）和RFS（RR=0.41;p=0.046），但不适用于CCL5阳性IC患者，除了N1+N2患者亚组，它与更好的操作系统相关联。我们建议CCL5表达可以作为肌层浸润性膀胱癌患者的预后和预测指标。
